{"filing":{"accession_number":"0001437749-26-031468","cik":"0000719135","ticker":"APYX","company_name":"Apyx Medical Corp","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"apyx20260929_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm"},"events":[{"id":35768,"run_id":32965,"accession_number":"0001437749-26-031468","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Apyx Medical announced publication of new clinical study data in a peer-reviewed journal demonstrating that Renuvion helium plasma radiofrequency technology produces measurable biological improvements in skin quality (increased elastin, reduced inflammation, favorable dermal remodeling). This is a material operational/product milestone—positive clinical evidence supporting the company's core product efficacy—but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.). The disclosure is clearly operational in nature and material to investor assessment of the company's product value proposition.","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39941,"accession_number":"0001437749-26-031468","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Apyx Medical announced publication of new clinical study data in a peer-reviewed journal demonstrating that Renuvion helium plasma radiofrequency technology produces measurable biological improvements in skin quality (increased elastin, reduced inflammation, favorable dermal remodeling). This is a material operational/product milestone—positive clinical evidence supporting the company's core product efficacy—but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.). The disclosure is clearly operational in nature and material to investor assessment of the company's product value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:20:37.964523+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39941,"accession_number":"0001437749-26-031468","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Apyx Medical announced publication of new clinical study data in a peer-reviewed journal demonstrating that Renuvion helium plasma radiofrequency technology produces measurable biological improvements in skin quality (increased elastin, reduced inflammation, favorable dermal remodeling). This is a material operational/product milestone—positive clinical evidence supporting the company's core product efficacy—but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.). The disclosure is clearly operational in nature and material to investor assessment of the company's product value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:20:37.964523+00:00","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-09-29"}]}